PMID- 30722063
OWN - NLM
STAT- MEDLINE
DCOM- 20200427
LR  - 20200427
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 104
IP  - 6
DP  - 2019 Jun 1
TI  - Unacylated Ghrelin Does Not Acutely Affect Substrate Metabolism or Insulin 
      Sensitivity in Men With Type 2 Diabetes.
PG  - 2435-2442
LID - 10.1210/jc.2018-02601 [doi]
AB  - OBJECTIVE: Unacylated ghrelin (UAG) is suggested to improve insulin sensitivity 
      and may have therapeutic potential. We therefore tested the effects of 
      intravenous UAG infusion on glucose and lipid metabolism, insulin sensitivity, 
      and energy expenditure in men with type 2 diabetes mellitus (T2DM). DESIGN: 
      Randomized, double-blind, placebo-controlled crossover study performed at a 
      university hospital clinical research center. METHODS: Ten men with T2DM 
      completed two study days: (i) 6-hour UAG infusion (1 microg/kg/h) and (ii) 6-hour 
      placebo infusion. The patients were investigated in the basal postabsorptive 
      state for 4 hours, followed by a hyperinsulinemic clamp for 2 hours. The turnover 
      rates of glucose and fatty acids were assayed by isotope tracer techniques. 
      Energy expenditure was measured by indirect calorimetry. RESULTS: The mean plasma 
      UAG was 64.1 +/- 11.3 pg/mL at baseline and increased >50-fold during UAG infusion. 
      Plasma glucose was 7.0 +/- 0.3 mmol/L during UAG infusion vs 6.7 +/- 0.4 mmol/L 
      placebo infusion (P = 0.43) at baseline and was not affected by UAG. During the 
      hyperinsulinemic clamp, glucose infusion rates were 4.69 +/- 0.56 mg/kg/min during 
      UAG infusion vs 4.98 +/- 0.43 mg/kg/min during placebo infusion (P = 0.66). UAG did 
      not affect glucose oxidation, nonoxidative glucose disposal, lipolysis, energy 
      expenditure, or respiratory exchange rate. CONCLUSIONS: This study found that 
      native UAG exposure did not exert acute metabolic effects in men with T2DM.
CI  - Copyright (c) 2019 Endocrine Society.
FAU - Vestergaard, Esben Thyssen
AU  - Vestergaard ET
AD  - Medical Research Laboratory, Aarhus University, Aarhus N, Denmark.
AD  - Department of Pediatrics, Randers Regional Hospital, Randers, Denmark.
FAU - Jessen, Niels
AU  - Jessen N
AD  - Department of Clinical Medicine, Research Laboratory for Biochemical Pathology, 
      Aarhus University Hospital, Aarhus N, Denmark.
AD  - Steno Diabetes Center Aarhus, Aarhus N, Denmark.
AD  - Department of Biomedicine, Aarhus University, Aarhus, Denmark.
AD  - Department of Clinical Pharmacology, Aarhus University, Aarhus C, Denmark.
FAU - Moller, Niels
AU  - Moller N
AD  - Medical Research Laboratory, Aarhus University, Aarhus N, Denmark.
AD  - Department of Diabetes and Endocrinology, Aarhus University Hospital, Aarhus N, 
      Denmark.
FAU - Jorgensen, Jens Otto Lunde
AU  - Jorgensen JOL
AD  - Medical Research Laboratory, Aarhus University, Aarhus N, Denmark.
AD  - Department of Diabetes and Endocrinology, Aarhus University Hospital, Aarhus N, 
      Denmark.
LA  - eng
SI  - EudraCT/2013-000022-63
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Ghrelin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Acylation
MH  - Adult
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*metabolism
MH  - Double-Blind Method
MH  - Energy Metabolism
MH  - Ghrelin/*pharmacology
MH  - Glucose/metabolism
MH  - Humans
MH  - *Insulin Resistance
MH  - Lipolysis
MH  - Male
MH  - Middle Aged
EDAT- 2019/02/06 06:00
MHDA- 2020/04/28 06:00
CRDT- 2019/02/06 06:00
PHST- 2018/12/03 00:00 [received]
PHST- 2019/01/30 00:00 [accepted]
PHST- 2019/02/06 06:00 [pubmed]
PHST- 2020/04/28 06:00 [medline]
PHST- 2019/02/06 06:00 [entrez]
AID - 5306250 [pii]
AID - 10.1210/jc.2018-02601 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2019 Jun 1;104(6):2435-2442. doi: 10.1210/jc.2018-02601.